Bladder Cancer Stage and Mortality: Urban Vs. Rural Residency
Overview
Public Health
Authors
Affiliations
Objective: Relative to urban populations, rural patients may have more limited access to care, which may undermine timely bladder cancer (BCa) diagnosis and even survival.
Methods: We tested the effect of residency status (rural areas [RA < 2500 inhabitants] vs. urban clusters [UC ≥ 2500 inhabitants] vs. urbanized areas [UA, ≥50,000 inhabitants]) on BCa stage at presentation, as well as on cancer-specific mortality (CSM) and other cause mortality (OCM), according to the US Census Bureau definition. Multivariate competing risks regression (CRR) models were fitted after matching of RA or UC with UA in stage-stratified analyses.
Results: Of 222,330 patients, 3496 (1.6%) resided in RA, 25,462 (11.5%) in UC and 193,372 (87%) in UA. Age, tumor stage, radical cystectomy rates or chemotherapy use were comparable between RA, UC and UA (all p > 0.05). At 10 years, RA was associated with highest OCM followed by UC and UA (30.9% vs. 27.7% vs. 25.6%, p < 0.01). Similarly, CSM was also marginally higher in RA or UC vs. UA (20.0% vs. 20.1% vs. 18.8%, p = 0.01). In stage-stratified, fully matched CRR analyses, increased OCM and CSM only applied to stage T1 BCa patients.
Conclusion: We did not observe meaningful differences in access to treatment or stage distribution, according to residency status. However, RA and to a lesser extent UC residency status, were associated with higher OCM and marginally higher CSM in T1N0M0 patients. This observation should be further validated or refuted in additional epidemiological investigations.
Socioeconomic disparities in survival of patients with non-muscle invasive urothelial carcinoma.
Baralo B, Daniels P, McIntire C, Thirumaran R, Melson J, Paul A World J Urol. 2025; 43(1):120.
PMID: 39937268 PMC: 11821756. DOI: 10.1007/s00345-024-05422-2.
Chung Y, Lee S, Jeong B, Ku J, Kwon T, Kim T J Robot Surg. 2024; 19(1):1.
PMID: 39549165 PMC: 11568977. DOI: 10.1007/s11701-024-02099-y.
Escott M, Yi Y, Foret A, Li T, Hsieh M, Delacroix Jr S Cancer Med. 2024; 13(12):e7301.
PMID: 38923853 PMC: 11199337. DOI: 10.1002/cam4.7301.
Adamczak B, Kuznik Z, Makles S, Wasilewski A, Kosendiak A Healthcare (Basel). 2024; 12(1).
PMID: 38200965 PMC: 10779175. DOI: 10.3390/healthcare12010059.
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States.
Pompa I, Qi D, Ghosh A, Goldberg S, Chino F, Efstathiou J Bladder Cancer. 2024; 9(4):345-353.
PMID: 38174126 PMC: 10759801. DOI: 10.3233/BLC-230062.